QuidelOrtho upgraded by Jefferies with a new price target
$QDEL
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/8/2025 | $44.00 | Hold → Buy | Jefferies |
| 12/11/2024 | $44.00 → $50.00 | Neutral → Buy | Citigroup |
| 12/10/2024 | $43.00 | Hold | Jefferies |
| 9/19/2024 | $42.00 → $50.00 | Neutral | UBS |
| 9/5/2024 | $40.00 → $57.00 | Hold → Buy | Craig Hallum |
| 3/4/2024 | $70.00 → $42.00 | Neutral → Sell | UBS |
| 2/14/2024 | $66.00 → $37.00 | Neutral → Underweight | JP Morgan |
| 12/11/2023 | $95.00 → $72.00 | Buy → Neutral | Citigroup |
8-K - QuidelOrtho Corp (0001906324) (Filer)
SD - QuidelOrtho Corp (0001906324) (Filer)
8-K - QuidelOrtho Corp (0001906324) (Filer)
―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance――Company Plans to Discontinue Savanna® Platform Development――Company Reaffirms Full Year 2025 Financial Guidance ――Company to Host Conference Call Today at 5:00 p.m. ET― SAN DIEGO, June 3, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced a refocusing of its molecular diagnostics strategy. This strategy includes the intent to acquire full ownership of LEX Diagnostics after 510(k) clearance by the U.S. Food and Drug Administrat
QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 45th Annual Growth Stock Conference, Wednesday, June 4, 2025 Members of QuidelOrtho's management team will participate in a presentation at 9:00 a.m. ET / 6:00 a.m. PT. Jefferies Global Healthcare Conference, Thursday, June 5, 2025 Members of QuidelOrtho's management team will participate in a fireside chat at 8:45 a.m. ET / 5:45 a.m. PT. Interested parties can access the liv
― Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening ― ― Strong execution on cost-savings initiatives driving improved margins and profitability ― ― Company maintains full-year 2025 financial guidance ― First Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $693 million, as reported Non-respiratory revenue was $573 million, which was flat to the prior year period as reported and an increase of 2% in constant currency Labs revenue grew 5% as reported and 7% in constant currency Donor Screening revenue declined by 62% as the Company continues to wind down the U.S. portion of
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00
Citigroup upgraded QuidelOrtho from Neutral to Buy and set a new price target of $50.00 from $44.00 previously
Jefferies initiated coverage of QuidelOrtho with a rating of Hold and set a new price target of $43.00
4/A - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)